Broadcast Date: Friday, March 31, 2023
from 12:00 pm to 1:00 pm (ET)
Overview:
A “skinny label” is a label on a generic pharmaceutical product that “carves out” (eliminates) the listing of an indication or disease for which the reference drug has been approved. Generic manufacturers use skinny labels to try to avoid “inducing” infringement of branded patents that claim the treatment of the carved-out diseases. But sometimes infringement can still be found. In what many see as a pivotal case – Glaxo v. Teva – the Federal Circuit found infringement despite a skinny label. The panelists will discuss the law of induced infringement before and after Glaxo v. Teva; what that case portends for the future; and what the U.S. Supreme Court may or may not do with the case.
- The Law of Infringement by Inducement Generally
- Inducement in the Context of Hatch-Waxman Cases – Pre-Glaxo v. Teva
- Glaxo v. Teva at the District Court Case
- Glaxo v. Teva at the Federal Circuit
- Supreme Court Petition for Certiorari
- Perspectives – Discussion
Credit:
Course Level:
Intermediate
Advance Preparation:
Print and review course materials
Method of Presentation:
On-Demand Webcast
Prerequisite:
General knowledge of patent laws
Course Code:
1410566
NY Category of CLE Credit:
Areas of Professional Practice
Total Credit:
1.0 CLE
How to Claim CLE Credits Per State:
https://knowledgewebcasts.com/how-to-claim-cle-credits-per-state/
CLE State Requirements:
https://knowledgewebcasts.com/cle-state-requirements/
CPE State Requirements:
Speaker Panel:
Jason A. Lief, Partner
27 Years of Experience in Patent and
Intellectual Property Cases
Windels Marx Lane & Mittendorf, LLP
Jason Lief is a premier patent trial lawyer with 27 years of experience. He has litigated and tried dozens of major patent and other intellectual property cases on behalf of some of the world’s most innovative and dynamic companies, often involving billion-dollar products. Applying his legal and scientific training, Jason has established a reputation for winning outcomes and courtroom excellence.
Jason’s cases include major Hatch-Waxman pharmaceutical litigations (Zantac®, Wellbutrin®, Wellbutrin SR®, Wellbutrin XL®, Ceftin®, Intuniv®, Vyvanse®, Oxtellar XR®, Angiomax®, and Lialda®), as well as biotech, chemical, and consumer product patent cases. Jason has also litigated trade secret, trademark, copyright, and IP contract disputes.
Pablo Hendler, Partner
Potomac Law Group, PLLC
Pablo Hendler has counseled clients for nearly 30 years on intellectual property matters. Pablo’s focus has been on life science patent litigation, including Hatch-Waxman, biologic, and medical device cases. His clients have consistently praised him as an “excellent lawyer” and a “sharpshooting” litigator, particularly for his “sterling” work in ANDA litigations. They are comforted by his “seen-and-done-it-all experience.” Pablo is also actively involved in pro bono immigration work.
Agenda:
Jason A. Lief, Partner
Windels Marx Lane & Mittendorf, LLP
and
Pablo Hendler, Partner
Potomac Law Group, PLLC
- The Law of Infringement by Inducement Generally
- Inducement in the Context of Hatch-Waxman Cases – Pre-Glaxo v. Teva
- Glaxo v. Teva at the District Court Case
- Glaxo v. Teva at the Federal Circuit
- Supreme Court Petition for Certiorari
- Perspectives – Discussion
Date & Time:
Friday, March 31, 2023
12:00 pm to 1:00 pm (ET)
Who Should Attend:
- Intellectual Property Lawyers/Counsel
- Biotechnology/Pharmaceutical Lawyers
- Patent Attorneys
- Patent Licensing Attorneys
- FDA Attorneys
- Patent Managers
- Patent Examiners
- General Counsel from Biotechnology/Pharmaceutical Industries
Join Over 160,000 Professionals Empowering Their Careers
Learn anywhere from over 3000+ live and recorded CLE, CPE & Technology Webcasts.